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KidneyUrinary Biomarkers to Identify Autosomal
Dominant Polycystic Kidney Disease Patients
With a High Likelihood of Disease Progression
A. Lianne Messchendorp1, Esther Meijer1, Wendy E. Boertien1, Gerwin E. Engels2,
Niek F. Casteleijn1, Edwin M. Spithoven1, Monique Losekoot3, Johannes G.M. Burgerhof4,
Dorien J.M. Peters5 and Ron T. Gansevoort1; on behalf of the DIPAK Consortium
1Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;
2HaemoScan bv, Groningen, the Netherlands; 3Department of Clinical Genetics, Leiden University Medical Center, Leiden, the
Netherlands; 4Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the
Netherlands; and 5Department of Human Genetics, Leiden University Medical Center, Leiden, the NetherlandsIntroduction: The variable disease course of autosomal dominant polycystic kidney disease (ADPKD)
makes it important to develop biomarkers that can predict disease progression, from a patient perspective
and to select patients for renoprotective treatment. We therefore investigated whether easy-to-measure
urinary biomarkers are associated with disease progression and have additional value over that of
conventional risk markers.
Methods: At baseline, inﬂammatory, glomerular, and tubular damage markers were measured in 24-hour
urine collections (albumin, IgG, kidney injury molecule1 (KIM-1), N-acetyl-b-D-glucosaminidase (NAG), b2
microglobulin (b2MG), heart-type fatty acid binding protein (HFABP), macrophage migration inhibitory
factor (MIF), neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemotactic protein1
(MCP-1). Disease progression was expressed as annual change in estimated glomerular ﬁltration rate
(eGFR, Chronic Kidney Disease EPIdemiology equation), measured glomerular ﬁltation rate (mGFR, using
125I-iothalamate), or height-adjusted total kidney volume (htTKV). Multivariable linear regression was used
to assess associations of these markers independent of conventional risk markers.
Results: A total of 104 ADPKD patients were included (40  11 years, 39% female, eGFR 77  30, mGFR 79
 30 ml/min per 1.73 m2 and htTKV 852 [5101244] ml/m). In particular, b2MG and MCP-1 were associated
with annual change in eGFR, and remained associated after adjustment for conventional risk markers
(standardized b ¼ 0.35, P ¼ 0.001, and standardized b ¼ 0.29, P ¼ 0.009, respectively). Adding b2MG and
MCP-1 to a model containing conventional risk markers that explained annual change in eGFR signiﬁcantly
increased the performance of the model (ﬁnal R2 ¼ 0.152 vs. 0.292, P ¼ 0.001). Essentially similar results
were obtained when only patients with an eGFR$ 60 ml/min per 1.73 m2 were selected, or when change in
mGFR was studied. Associations with change in htTKV were less strong.
Conclusion: Urinary b2MG and MCP-1 excretion were both associated with GFR decline in ADPKD, and
had added value beyond that of conventional risk markers. These markers therefore have the potential to
serve as predictive tools for clinical practice.
Kidney Int Rep (2018) 3, 291–301; https://doi.org/10.1016/j.ekir.2017.10.004
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T he age at which patients with autosomal dominantpolycystic kidney disease (ADPKD) will reach end-
stage kidney disease (ESKD) shows large interindividual
variability,1 even between family members that share
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International Reports (2018) 3, 291–301progression has become important, now that the ﬁrst
therapeutic options for ADPKD have emerged.3,4 Espe-
cially patients with a high likelihood of rapid disease
progression should be selected for treatment, because
in such patients the beneﬁt-to-risk ratio of treatment is
expected to be optimal.5,6
Currently, several variables are available to predict
disease progression in ADPKD. Glomerular ﬁltration
rate (GFR) indexed for age is a strong predictor but is
less sensitive in early stages of this disease, when GFR
can remain in the normal range due to compensatory291
CLINICAL RESEARCH AL Messchendorp et al.: Urinary biomarkers and ADPKD disease progressionhyperﬁltration, while cysts are progressively formed.1
Therefore, much attention has been focused on total
kidney volume (TKV) as a predictor.1,7 Furthermore
disease progression is inﬂuenced by the ADPKD
genotype, with patients with a PKD1 mutation, espe-
cially truncating mutations, progressing faster toward
ESKD compared to patients with a PKD2 mutation.2
However, assessment of TKV and genotype is labo-
rious and expensive, and their associations with the
rate of disease progression are limited at an individual
patient level. Therefore, new risk markers need to be
developed that, either alone or in combination with
conventional risk markers, can predict the rate of
disease progression in ADPKD.
Because ADPKD is a tubular disease with an
inﬂammatory component, measurement of urinary
tubular damage and inﬂammation markers is of
interest, especially because these markers are relatively
inexpensive and easy to measure. Several cross-
sectional studies have shown that these markers are
associated with ADPKD severity, assessed as GFR and
TKV.8–11 In this study, we aimed to determine, in a
longitudinal setting, whether urinary tubular damage
and inﬂammation markers are associated with rate of
ADPKD progression assessed as annual change in GFR
and TKV, and whether these markers have added value
beyond that of currently used risk markers.
METHODS
Setting and Subjects
From January 2007 until September 2012, a total of 133
ADPKD patients from the University Medical Center
Groningen were included in an observational study.
The diagnosis of APDKD was made based upon the
revised Ravine criteria.12 Patients were considered
ineligible if they received kidney replacement therapy,
had undergone kidney surgery, were unable to
undergo magnetic resonance imaging, or had other
systemic diseases or used treatments or medications
potentially affecting kidney function, such
as calcineurin inhibitors or nonsteroidal anti-
inﬂammatory drugs (NSAIDs).9,10 For the present
study, 29 patients were excluded because they had a
follow up time < 1 year, leaving 104 patients for
analysis. The study was performed in adherence to the
Declaration of Helsinki, and all participants gave
written informed consent. The review board of the
University Medical Center Groningen deemed this
study exempt from assessment because of its post hoc
exploratory nature.
Measurements
At the baseline visit, a physical examination was
performed, including blood pressure measurements.292Fasting blood samples were drawn for the measurement
of creatinine and PKD mutation analyses. The esti-
mated GFR (eGFR) was calculated using the 2009
Chronic Kidney Disease EPIdemiology (CKD-EPI)
equation.13 The PKD mutation analysis was performed
with DNA isolation using PUREGENE nucleic acid
puriﬁcation chemistry on the AUTOPURE LS 98 plat-
form (Qiagen, Venlo, the Netherlands), followed by
sequencing of ampliﬁed coding exons directly (exons
3446), or on long-range polymerase chain reaction
products (exons 133).14 In addition, measured GFR
(mGFR) was determined by a constant infusion method
with 125I-iothalamate, and magnetic resonance imaging
was performed to assess TKV, using a standardized
abdominal magnetic resonance imaging protocol
without the use of i.v. contrast. TKV was measured on
T2-weighted coronal images using Analyze direct 9.0
(AnalyzeDirect, Inc., Overland Park, KS) by classical
volumetry (i.e., manual tracing) and adjusted for height
(htTKV).
The day before the baseline visit, patients collected a
24-hour urine, of which samples were stored frozen
at 80C that were used to measure albumin as a
general kidney damage marker; IgG as a glomerular
damage marker; and b2 microglobulin (b2MG), kidney
injury molecule1 (KIM-1), and N-acetyl-b-D-glucosa-
minidase (NAG) as proximal tubular damage markers;
heart-type fatty acid binding protein (HFABP) as a
distal tubular damage marker; and macrophage migra-
tion inhibitory factor (MIF), neutrophil gelatinase-
associated lipocalin (NGAL), and monocyte chemo-
tactic protein1 (MCP-1) as inﬂammation markers.15–23
Urinary albumin was determined by immunone-
phelometry (BNII, Dade Behring Diagnostics, Deerﬁeld,
Illinois). Urinary IgG, HFABP (Hytest, Turku, Finland),
b2MG (Anogen, Mississauga, Ontario, Canada), KIM-1,
MIF, NGAL, and MCP-1 (R&D Systems, Minneapolis,
Minnesota) were measured by enzyme-linked immu-
nosorbent assay. NAG was measured with a modiﬁed
enzyme assay according to Lockwood and corrected for
nonspeciﬁc conversion (HaemoScan, Groningen, the
Netherlands). Urine samples were diluted twice for
KIM-1, b2MG, MCP-1, and MIF, 5 times for HFABP,
and 100 times for NGAL and IgG. Detection limit for
albumin was 0.003 mg/ml, for IgG 220 ng/ml, for
b2MG 18 ng/ml, for KIM-1 0.087 ng/ml, for HFABP
0.38 ng/ml, for MIF 0.06 ng/ml, for NGAL 22 ng/ml,
and for MCP-1 0.04 ng/ml. The intra- and interassay
coefﬁcients of variation were 2.2% and 2.6% for
albumin, 6.3% and 8.5% for b2MG, 7.4% and 14.5%
for KIM-1, 3.1% and 13.7% for NAG, 9.3% and 17.6%
for H-FABP, 8.3% and 12.7% for MCP-1, 5.2% and
9.2% for MIF, and 6.8% and 19.6% for NGAL,
respectively.Kidney International Reports (2018) 3, 291–301
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Normally distributed data are expressed as mean  SD,
whereas nonnormally distributed data are expressed
as median with interquartile range (IQR). For cross-
sectional comparison of baseline data, healthy con-
trols (matched for sex and age) were asked to partici-
pate. These subjects had no medical history of
cardiovascular and/or kidney disease, no medication
use, normal blood pressure (< 140 systolic and < 90
diastolic) and preserved eGFR (> 60 ml/min per 1.73
m2).9 Differences between patients with ADPKD and
healthy controls were tested using the 2-sample t test
when normally distributed or a MannWhitney test
when not normally distributed. A c2 test was used in
the case of categorical data.
Our primary endpoint was annual change in eGFR,
and our secondary endpoints were annual change in
mGFR and htTKV. These endpoints were calculated as
follow-up minus baseline value divided by follow-up
time in years, because there was only 1 follow-up
value available for mGFR and htTKV. Annual change
in eGFR was calculated in the same way so as to be in
line with the analyses of the secondary endpoints.
Annual change in eGFR was selected as our primary
endpoint because disease progression is clinically
assessed as eGFR decline and because more patients had
data available for this endpoint than for change in
mGFR. Multivariable linear regression analysis was
used to investigate the associations of the various uri-
nary biomarkers with annual change in eGFR, mGFR,
and htTKV, with sequential adjustment for conven-
tional risk markers (sex and baseline age, eGFR or
mGFR, htTKV, and PKD mutation). All urinary bio-
markers were log transformed to fulﬁll the requirement
of normal distribution of the residuals except for
albumin and MCP-1 excretion for annual change in
htTKV. A subset of the included patients (27%) used
tolvaptan between the baseline and follow-up assess-
ment; therefore the associations of the biomarkers with
all outcome measurements were additionally adjusted
for tolvaptan use.
To investigate which variables had the strongest
associations with annual change in eGFR, a stepwise
backward linear regression analysis was performed for
which the biomarkers with a univariate a # 0.25 were
selected, together with the conventional risk markers.
To investigate whether biomarkers had added
prognostic value beyond that of conventional risk
markers, we tested the difference in R squared (R2) for
the various models. We ﬁrst adjusted the R2 for opti-
mism using bootstrapping.24 One thousand random
samples of equal size were taken from the complete
dataset using sampling with replacement. In these
bootstrap samples, the coefﬁcients of the ﬁnalKidney International Reports (2018) 3, 291–301regression model were estimated (Mb,boot) and tested in
the original sample (Mb,orig). Optimism was deﬁned as
R2(Mb,boot) – R
2(Mb,orig). The R
2 was adjusted for
optimism by subtracting the optimism from the
original R2 of the original dataset. We used the original
data to select the ﬁnal model from the stepwise back-
ward analysis and subsequently adjusted this speciﬁc
model for optimism. The for-optimismadjusted R2 of
the various models were compared with nested models
using an F test. Akaike weight w(AIC) was used to
compare the relative quality of the various unnested
models.25
As sensitivity analyses, we tested the aforemen-
tioned associations, ﬁrst in patients with a preserved
kidney function only (eGFR $ 60 ml/min per 1.73 m2),
and second in patients not using tolvaptan between the
baseline and follow-up assessment. Third, we repeated
the primary analysis with annual change in eGFR
calculated as slope, with slope calculated by at least 3
eGFR measurements over > 1 year. This endpoint was
chosen for the sensitivity analysis instead of the
primary analysis because it could be performed only in
a subset of patients. Fourth, we performed fractional
polynomial regression analyses to test whether the
associations between biomarkers and annual change in
eGFR were linear.
Finally, we investigated how well urinary biomarker
excretion was associated with annual change in eGFR
compared to the Mayo htTKV classiﬁcation.26 There-
fore we transformed the urinary biomarker excretion in
a urinary biomarker score (i.e., the combined ranking
of the tertiles of the best-performing biomarkers) and
bootstrapped the multivariable regression analyses
with 1000 repetitions to obtain P values for the
difference in the optimism-adjusted R2 between the
models. The relative quality of the Mayo htTKV
classiﬁcation and the urinary biomarker score were
compared by calculating the w(AIC).
Analyses were performed with SPSS version 22.0
(SPSS Inc., Chicago, IL) and R version 3.2.2. A 2-sided
P < 0.05 was considered statistically signiﬁcant.RESULTS
Subject Characteristics
Overall, our cohort was characterized by a relatively
young population with a preserved kidney function.
Healthy controls had a similar age and sex but had a
higher eGFR (Table 1). As shown in Table 2, all urinary
biomarker excretions were signiﬁcantly higher in pa-
tients than in age- and sex-matched controls. The
correlation amongst the various biomarkers is shown in
Supplementary Table S1. All 104 patients had a follow-
up eGFR, with a follow-up time of 3.82  1.23 years293
Table 1. Baseline characteristics of ADPKD patients and control
subjects
Characteristic ADPKD (n [ 104) Control (n [ 102) P value
Female sex, % 39.4 42.2 0.69
Age, yr 40  11 39  12 0.66
Weight, kg 86  18 74  11 <0.001
Height, cm 180  10 178  8 0.06
BSA, m2 2.04  0.24 1.91  0.16 <0.001
SBP, mm Hg 129  12 122  12 <0.001
DBP, mm Hg 79  9 72  8 <0.001
AHT, % 76.0 0.0 <0.001
RAASi, % 69.2 0.0 <0.001
eGFR, ml/min per 1.73 m2 77  30 103  12 <0.001
mGFR, ml/min per 1.73 m2 79  30 — —
htTKV, ml/m 852 (510L1244) — —
PKD mutation, %
PKD1 truncating 44.2 — —
PKD1 nontruncating 28.9 — —
PKD2 12.5 — —
Unknown 1.9 — —
Missing 12.5 — —
ADPKD, autosomal dominant polycystic kidney disease; AHT, anti-hypertensive therapy;
BSA, body surface area; DBP, diastolic blood pressure; GFR, estimated glomerular
ﬁltration rate; htTKV, height-adjusted total kidney volume; mGFR, measured glomerular
ﬁltration rate; PKD, polycystic kidney disease; RAASi, reninangiotensinaldosterone
system inhibitors; SBP, systolic blood pressure.
Variables are presented as mean  SD, or as median (interquartile range) in case of
nonnormal distribution.
Table 2. Urinary biomarker excretions in ADPKD patients versus
healthy control subjects
Urinary biomarker ADPKD Control P value
General
UAE (mg/24 h) 37.8 (14.2–117.8) 7.6 (6.2–12.8) <0.001
Glomerular
IgG (mg/24 h) 13.7 (4.2–43.4) 0.0 (0.0–0.0) <0.001
Proximal tubular
b2MG (mg/24 h) 201.1 (81.2–579.3) 78.4 (48.0–121.8) <0.001
KIM-1 (mg/24 h) 1.5 (1.0–2.2) 0.81 (0.4–1.3) <0.001
NAG (mg/24 h) 3.3 (0.8–8.1) 0.0 (0.0–2.4) <0.001
Distal tubular
HFABP (mg/24 h) 2.0 (1.3–3.2) 1.4 (1.0–2.2) 0.001
Inﬂammatory
MIF (ng/24 h) 176.0 (106.5–258.0) 129.5 (76.4–241.6) 0.02
NGAL (mg/24 h) 73.0 (29.2–158.1) 23.4 (16.3–30.9) <0.001
MCP-1 (ng/24 h) 699.2 (533.6–1098.6) 266.1 (175.3–396.9) <0.001
b2MG, b2 microglobulin; HFABP, heart-type fatty acid binding protein; KIM-1, kidney
injury molecule–1; MCP-1, monocyte chemotactic protein–1; MIF, macrophage migra-
tion inhibitory factor; NAG, N-acetyl-b-D-glucosaminidase; NGAL, neutrophil gelatinase-
associated lipocalin; UAE, urinary albumin excretion.
Variables are presented as median (interquartile range).
CLINICAL RESEARCH AL Messchendorp et al.: Urinary biomarkers and ADPKD disease progressionand an annual change in eGFR of 3.22  3.03 ml/min
per 1.73 m2. Follow-up mGFR was available for 92
patients, with a follow-up time of 3.76  1.23 years and
an annual change in mGFR of 3.10  2.97 ml/min per
1.73 m2. Follow-up htTKV was available for 81 patients,
with a follow-up time of 3.78  1.10 years and an
annual change in htTKV of 6.17%  5.66%.
Associations of Urinary Biomarkers With Rate of
Disease Progression
Both b2MG and MCP-1 were strongly associated with
annual change in eGFR and remained signiﬁcant after
adjustment for conventional risk markers (standardized
b ¼ 0.35, P ¼ 0.001, and standardized b ¼ 0.29,
P ¼ 0.009 respectively). Less strong but also signiﬁcant
after adjustment for conventional risk markers was
KIM-1 (standardized b ¼ 0.24, P ¼ 0.02) (Table 3).
Essentially similar results were obtained with annual
change in mGFR for b2MG, KIM-1, and MCP-1 (stan-
dardized b ¼ 0.25, P ¼ 0.03, standardized
b ¼ 0.25, P ¼ 0.03, and standardized b ¼ 0.21,
P ¼ 0.09, respectively) (Table 4), although these asso-
ciations were less strong compared to the associations
with annual change in eGFR. Figure 1 depicts the
univariate associations of the 2 biomarkers with the
strongest associations for annual change in eGFR in
ADPKD patients, stratiﬁed according to tertiles of
increasing levels of 24-hour urinary biomarker294excretion. KIM-1 and MCP-1 excretion were both
associated with annual change in htTKV in the crude
analyses, but these associations lost signiﬁcance after
adjustment for sex, baseline age, mGFR, and htTKV
(Table 5).
Added Value of Urinary Biomarkers Beyond
That of Conventional Risk Markers
In Table 6, the strength of the associations of various
models, including the 2 biomarkers with the strongest
associations with annual change in eGFR, are
compared. The R2 of the model with only the con-
ventional risk markers (model 1) was compared with
the model additionally including b2MG (model 2),
MCP-1 (model 3), or both markers (model 4). Model 4
had the best ﬁt for annual change in eGFR, with an R2
of 0.292 (P ¼ 0.001, P ¼ 0.03, and P ¼ 0.006 compared
to model 1, 2, and 3, respectively). Figure 2 displays the
combined ranking of tertiles of urinary b2MG and
MCP-1 excretion (urinary biomarker score) with annual
change in eGFR.
Selection of Variables With the Strongest
Association
Stepwise backward regression analysis was performed
to select the variables with the strongest associations
with annual change in eGFR. For this analysis age, sex,
baseline eGFR, baseline htTKV, PKD mutation, UAE,
b2MG, KIM-1, IgG, and MCP-1 were considered. The
ﬁnal model showed an R2 of 0.330 and included base-
line htTKV, PKD mutation, b2MG, and MCP-1 excre-
tion; KIM-1 excretion lost its signiﬁcance (Table 7).
UAE did also not remain signiﬁcantly associated, fromKidney International Reports (2018) 3, 291–301











St b P St b P St b P St b P
General
UAE –0.37 <0.001 –0.37 0.001 –0.27 0.02 –0.16 0.20
Glomerular
IgG –0.32 0.002 –0.32 0.003 –0.27 0.01 –0.22 0.07
Proximal tubular
b2MG –0.28 0.009 –0.30 0.006 –0.24 0.03 –0.25 0.03
KIM-1 –0.25 0.02 –0.24 0.03 –0.20 0.06 –0.25 0.03
NAG –0.13 0.23 –0.15 0.20 –0.03 0.82 –0.02 0.89
Distal tubular
HFABP 0.02 0.85 0.03 0.79 0.12 0.31 0.11 0.40
Inﬂammatory
MIF 0.10 0.34 0.10 0.35 0.10 0.35 0.04 0.74
NGAL –0.34 0.001 –0.46 <0.001 –0.38 0.002 –0.34 0.01
MCP-1 –0.41 <0.001 –0.40 <0.001 –0.29 0.01 –0.21 0.09
b2MG, b2 microglobulin; KIM-1, kidney injury molecule–1; mGFR, measured GFR; NAG,
N-acetyl-b-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; St b,
standardized b; HFABP, heart-type fatty acid binding protein; MCP-1, monocyte
chemotactic protein–1; MIF, macrophage migration inhibitory factor; UAE, urinary al-
bumin excretion.
Standardized b values and P values were calculated using multivariable linear
regression. Dependent variable is annual change in mGFR. Independent variables are
log transformed 24-h excretions of the various biomarkers.
aModel 1: adjusted for age and sex.
bModel 2: as for model 1 with additional adjustment for baseline mGFR and htTKV.
cModel 3: as for model 2 with additional adjustment for PKD mutation.











St b P St b P St b P St b P
General
UAE –0.34 0.001 –0.31 0.003 –0.17 0.13 –0.08 0.51
Glomerular
IgG –0.30 0.003 –0.28 0.004 –0.17 0.09 –0.12 0.27
Proximal tubular
b2MG –0.28 0.006 –0.29 0.004 –0.23 0.02 –0.35 0.001
KIM-1 –0.29 0.003 –0.28 0.005 –0.21 0.03 –0.24 0.02
NAG –0.11 0.27 –0.12 0.25 0.03 0.79 0.06 0.57
Distal tubular
HFABP 0.04 0.68 0.03 0.77 0.16 0.15 0.08 0.51
Inﬂammatory
MIF 0.10 0.35 0.10 0.34 0.12 0.19 0.07 0.48
NGAL –0.08 0.44 –0.18 0.11 0.04 0.75 0.05 0.70
MCP-1 –0.51 <0.001 –0.49 <0.001 –0.38 <0.001 –0.29 0.009
b2MG, b2 microglobulin; eGFR, estimated glomerular ﬁltration rate; HFABP, heart-type
fatty acid binding protein; KIM-1, kidney injury molecule 1; MCP-1, monocyte chemo-
tactic protein–1; MIF, macrophage migration inhibitory factor; NAG, N-acetyl-b- D-glu-
cosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; St b, standardized b;
UAE, urinary albumin excretion.
Standardized b values and P values were calculated using multivariable linear
regression. Dependent variable is annual change in eGFR. Independent variables are
log transformed 24-h excretions of the various biomarkers.
aModel 1: adjusted for age and sex.
bModel 2: as for model 1 with additional adjustment for baseline eGFR and htTKV.
cModel 3: as for model 2 with additional adjustment for PKD mutation.
AL Messchendorp et al.: Urinary biomarkers and ADPKD disease progression CLINICAL RESEARCHwhich we can conclude that these results were inde-
pendent of albuminuria. Of note, this ﬁnal model did
not outperform model 4 in Table 6, where all conven-
tional risk markers and both b2MG and MCP-1 were
included (P ¼ 0.43). The relative quality of each model
was tested with the w(AIC). This analysis indicated
that the model in Table 7 is the best model
(Supplementary Table S2).
Sensitivity Analyses
Several sensitivity analyses were performed to test the
robustness of our ﬁndings. First, we limited the analyses
to patients with an eGFR $ 60 ml/min per 1.73 m2 (n ¼
73). Only b2MG excretion remained signiﬁcantly asso-
ciated after adjustment for conventional risk markers
(standardized b ¼ 0.37, P ¼ 0.001). Second, we
repeated the analyses in patients not using tolvaptan
between the baseline and follow-up assessment (n¼ 76).
b2MG, KIM-1, and MCP-1excretion remained signiﬁ-
cantly associated with annual change in eGFR after
adjustment for conventional risk markers (standardized
b¼0.45P< 0.001, standardizedb¼0.31,P¼ 0.009,
and standardized b¼0.26, P¼ 0.05, respectively). Of
note, no signiﬁcant interactions were found between
tolvaptan use and biomarker excretion with annual
change in eGFR,mGFR, or htTKV. Repeating the primary
analyses with annual change in eGFR calculated as slope
instead of change in eGFR (n ¼ 96) showed again thatKidney International Reports (2018) 3, 291–301b2MGandMCP-1 remained signiﬁcantly associatedwith
annual change in eGFR after adjustment for conventional
risk markers (Supplementary Table S3). Finally,
Supplementary Figure S1 shows the distributions of in-
dividual data with respect to either b2MG or MCP-1
excretion versus annual change in eGFR and the
corresponding fractional polynomial regression
analyses. The regression lines are compatible with linear
associations.Comparison of Urinary Biomarkers With Risk
Classiﬁcation Based on htTKV Adjusted for Age
The performance of the urinary biomarker score was
compared to the performance of the Mayo htTKV
classiﬁcation. According to this classiﬁcation, 14.4% of
the patients of our cohort were classiﬁed as “atypical.”
From the patients with typical ADPKD, 3.5% were
assigned to class A, 11.8% to class B, 35.3% to class C,
28.2% to class D, and 21.2% to class E. Differences
between the subgroups in annual change in eGFR are
shown in Supplementary Figure S2. When performing
a multivariable linear regression analysis, the Mayo
htTKV classiﬁcation had a univariate R2 of 0.110 for
annual change in eGFR. The urinary biomarker score
had an R2 of 0.203 (P < 0.001). A comparison of the
relative quality of the separate models [w(AIC)] is
presented in Supplementary Table S4.295











St b P St b P St b P St b P
General
UAE 0.20 0.06 0.13 0.22 0.06 0.60 –0.01 0.94
Glomerular
IgG 0.07 0.55 0.04 0.69 –0.02 0.84 –0.08 0.51
Proximal tubular
b2MG 0.08 0.50 0.08 0.44 0.04 0.70 0.00 0.98
KIM-1 0.21 0.05 0.21 0.05 0.18 0.09 0.16 0.20
NAG 0.09 0.43 0.10 0.35 0.04 0.76 0.01 0.95
Distal tubular
HFABP –0.05 0.65 –0.00 0.99 –0.04 0.70 –0.04 0.77
Inﬂammatory
MIF 0.02 0.85 0.02 0.85 0.01 0.91 –0.01 0.96
NGAL –0.04 0.73 0.09 0.47 0.01 0.97 –0.03 0.82
MCP-1 0.28 0.008 0.23 0.03 0.18 0.15 0.06 0.66
b2MG, b2 microglobulin; HFABP, heart-type fatty acid binding protein; htTKV, height-
adjusted total kidney volume; KIM-1, kidney injury molecule–1; MCP-1, monocyte
chemotactic protein–1; MIF, macrophage migration inhibitory factor; NAG, N-acetyl-b-D-
glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; St. b, standardized
b; UAE, urinary albumin excretion.
Standardized b values and P values were calculated using multivariable linear
regression. Dependent variable is annual change in htTKV. Independent variables are
log transformed 24-h excretions of the various biomarkers, except for UAE and MCP-1.
aModel 1: adjusted for age and sex.
bModel 2: as for model 1 with additional adjustment for baseline mGFR and htTKV.
cModel 3: as for model 2 with additional adjustment for PKD mutation.
Figure 1. Associations of urinary b2 microglobulin (b2MG) (a) and
monocyte chemotactic protein1 (MCP-1) excretion (b) with annual
change in estimated glomerular ﬁltration rate (eGFR). Patients are
stratiﬁed according to tertiles of urinary biomarker excretion. P
values were calculated using analysis of variance with a post hoc
Bonferroni test.
CLINICAL RESEARCH AL Messchendorp et al.: Urinary biomarkers and ADPKD disease progressionDISCUSSION
In the present study, we investigated the association
between urinary biomarker excretion and disease
progression in ADPKD patients. Several cross-sectional
studies have shown that urinary markers are associated
with ADPKD severity, assessed as TKV and GFR.8–11 To
our knowledge, only 2 studies have previously inves-
tigated the association between urinary damage
markers and disease progression in a longitudinal296setting. Parikh et al. found no associations between
urinary interleukin-18 and NGAL and annual change
in eGFR and TKV in 107 ADPKD patients,11 whereas
Park et al. found no association between urinary NAG
and eGFR decline after 1 year in a cohort of 270 ADPKD
patients.27 In these 2 studies, urinary interleukin-18,
NGAL, and NAG concentrations were measured in
urine samples that were stored frozen. We have
previously shown that frozen storage decreases the
measured concentration of urinary biomarkers and
induces more variability.28 In particular, the increase in
variability can reduce the strength of associations, as
we have shown for urinary albumin concentration in
non-ADPKD subjects.29 Given these considerations, we
have cautioned against an overly skeptical view toward
the utility of urinary biomarkers to predict disease
progression in ADPKD.30 In the present study, we
investigated additional urinary biomarkers, and our
ﬁndings indicate that some of these markers are indeed
useful despite the variability of marker concentrations
induced by frozen storage.
It is assumed that cysts in ADPKD mainly originate
from the distal tubule and collecting ducts.31
Remarkably, in our study, especially the proximal
tubular marker b2MG and the inﬂammatory marker
MCP-1 were associated with kidney function decline,
suggesting that the proximal tubule and inﬂammation
may be involved in the pathophysiology of ADPKD.
We caution, however, against overinterpretation ofKidney International Reports (2018) 3, 291–301
Table 6. Models explaining annual change in eGFR without and with urinary biomarkers (n ¼ 83)
Variable
Model 1a Model 2b Model 3c Model 4d
St b P R2 St b P R2 St b P R2 St b P R2
0.152 0.247e 0.216e 0.292f
Age 0.20 0.17 0.11 0.44 0.13 0.37 0.05 0.69
Male sex –0.07 0.51 –0.05 0.63 –0.08 0.41 –0.06 0.51
eGFR 0.13 0.34 –0.04 0.79 0.05 0.73 –0.09 0.51
htTKV –0.44 <0.001 –0.43 <0.001 –0.30 0.009 –0.31 0.004
PKD2 (ref)g
PKD1 truncating –0.44 0.008 –0.51 0.001 –0.32 0.05 –0.41 0.009
PKD1 nontruncating –0.45 0.004 –0.49 0.001 –0.35 0.02 –0.40 0.005
b2MG –0.35 0.001 –0.31 0.002
MCP-1 –0.33 0.003 –0.28 0.008
b2MG, b2 microglobulin; eGFR, estimated glomerular ﬁltration rate; htTKV, height-adjusted total kidney volume; MCP-1, monocyte chemotactic protein–1; PKD, polycystic kidney disease;
St b, standardized b.
Standardized b and P values were calculated using multivariable linear regression. Dependent variable is annual change in eGFR. Independent variables are age, sex, baseline eGFR,
baseline htTKV, PKD mutation, b2MG, and MCP-1.
aModel 1: adjusted for age, sex, baseline eGFR, baseline htTKV and PKD mutation.
bModel 2: as for model 1 plus b2MG.
cModel 3: as for model 1 plus MCP-1.
dModel 4: as for model 1 plus b2MG and MCP-1.
eSignificant compared to model 1 (P ¼ 0.003 for model 2 and P ¼ 0.02 for model 3).
fSignificant compared to models 1, 2, and 3 (P ¼ 0.001, P ¼ 0.03, and P ¼ 0.006, respectively).
gPKD mutation was used as dummy variable with PKD2 as reference group.
Figure 2. Association of the combined ranking of tertiles of urinary
b2 microglobulin (b2MG) and monocyte chemotactic protein1
(MCP-1) excretion (urinary biomarker score) with annual change in
estimated glomerular ﬁltration rate (eGFR). P values were calculated
using analysis of variance with a post hoc Bonferroni test.
AL Messchendorp et al.: Urinary biomarkers and ADPKD disease progression CLINICAL RESEARCHour ﬁndings, because one should be aware of the
strengths and limitations of the various assays. One
assay is more reproducible than the other, and some
markers are more subjected to degradation during
long frozen storage than others.28,32 Moreover, in-
sights about the origin of certain markers may change,
which, for example, is the case for urinary NGAL
concentration. Although we consider it to be a general
inﬂammatory marker of kidney damage, others have
recently suggested that the collecting duct may be the
main source of urinary NGAL.33 The fact that we did
not ﬁnd associations between some markers (such as
the distal tubular damage marker HFABP) and disease
progression should therefore not lead to conclusions
as to which parts of the renal tubule are not involved
with cystogenesis.
Surprisingly, the markers that we studied did not
show associations with kidney growth. This may be due
to insufﬁcient power, as only 81 patients had a follow-up
htTKV. On the other hand, it may also indicate that
kidney growth represents a pathophysiological phe-
nomenon other than kidney function decline in terms of
urinary biomarkers. Of note, in our cohort there was
considerable variability in annual change in htTKV and
also in annual change in eGFR. However, the variability
in these rates of disease progression are comparable to
numbers thatwere found in other cohort studies, such as
the control groups in the TEMPO (Tolvaptan Efﬁcacy
and safety in Management of autosomal dominant
Polycystic kidney disease and Its Outcome) 3:4 trial and
the HALT-PKD (Halt Progression of Polycystic Kidney
Disease) trials.4,34–36 This variability in rate of disease
progression emphasizes furthermore the correctness ofKidney International Reports (2018) 3, 291–301the practical rationale of our study, i.e., that because of
high variability in rate of disease progression, markers
are needed to predict prognosis and select patients for
treatment.
Irazabal et al. recently developed a prognostic model
based on htTKV and age (the Mayo htTKV classiﬁca-
tion).26 The overall value of this model to predict
kidney function decline and incidence of ESKD is good;297
Table 7. Results of the stepwise backward regression analysis with
annual change in eGFR as dependent variable (n ¼ 84)




PKD1 truncating –0.45 0.002
PKD1 nontruncating –0.44 0.002
b2MG –0.30 0.001
MCP-1 –0.26 0.01
b2MG, b2 microglobulin; eGFR, estimated glomerular ﬁltration rate; htTKV, height-
adjusted total kidney volume; MCP-1, monocyte chemotactic protein–1; PKD, polycy-
stic kidney disease; St b, standardized b.
Standardized b and P values were calculated using multivariable linear regression.
Dependent variable is annual change in eGFR. Independent variables are baseline
htTKV, PKD mutation, b2MG, and MCP-1.
aPKD mutation was used as dummy variable with PKD2 as reference group.
CLINICAL RESEARCH AL Messchendorp et al.: Urinary biomarkers and ADPKD disease progressionhowever, information on type of PKD mutation was
not included in that study. In line with this predictive
ability, we found that htTKV was strongly associated
with annual change in eGFR. Of note, our results
showed that type of PKD mutation remained associated
with annual change in eGFR after adjustment for
htTKV, indicating that type of PKD mutation has
added value on top of baseline htTKV to predict kidney
function decline. This is the ﬁrst study to show such
added value. Importantly, when we performed a
stepwise backward analysis, urinary b2MG and MCP-1
excretion remained signiﬁcantly associated with annual
change in eGFR even after adjustment for htTKV and
type of PKD mutation (Table 7).
The advantage of urinary biomarkers is especially
that their measurement is relatively easy and inex-
pensive compared to measurement of TKV and PKD
mutation analysis. Based on our results, one might
therefore also consider using only urinary biomarkers
for the prediction of kidney function decline when not
all resources are available to measure TKV and to
perform PKD mutation analysis. The regression models
in this study show a relatively low R2, which has also
been found in other studies investigating disease pro-
gression in ADPKD.37–39 This suggests that to reliably
predict prognosis in ADPKD, multiple markers should
probably be used together, to achieve adequate risk
prediction. Our data suggest that, in this respect,
including urinary excretion of tubular damage and
inﬂammation markers on top of eGFR and htTKV
should be considered a candidate approach.
Now, with vasopressin V2 receptor antagonists and
possibly with somatostatin analogues the ﬁrst thera-
peutic options for ADPKD have emerged, and it is
important to be able to identify patients with a high
likelihood of rapid disease progression at an early stage
of their disease course. These patients especially can
beneﬁt from lifelong therapies with respect to absolute298gain in dialysis-free years. For this reason, we per-
formed a sensitivity analysis taking only patients into
account with a relatively preserved kidney function
(eGFR $ 60 ml/min per 1.73 m2). Even in this sub-
group, urinary b2MG excretion was still associated
with rate of kidney function decline, although the as-
sociation with urinary MCP-1 excretion did not reach
statistical signiﬁcance, probably due to insufﬁcient
power.
Our data should be interpreted with caution,
because our study has limitations. First, our cohort
consisted of a relatively small number of ADPKD
patients. For this reason, we adjusted our models for
optimism by bootstrapping, which minimizes the risk
of overﬁtting of data. In addition, we found similar
associations with the various endpoints that were
studied, including annual change in eGFR calculated as
slope, suggesting that our results are robust. Second,
we used data of some patients in our cohort who were
taking the vasopressin V2 receptor antagonist
tolvaptan between the baseline and follow-up visit,
which could have inﬂuenced our results. To investigate
this, a sensitivity analysis was performed, selecting
only patients who had not used tolvaptan. Similar
results were found with multivariable linear regres-
sion. In addition, no statistical interactions were found
between biomarker excretions and tolvaptan use in
their associations with each outcome variable. In the
near future, the use of mixed populations for research,
with some patients using tolvaptan and others not
using it, will be everyday practice, as tolvaptan has
been granted marketing authorization in Europe and
other countries around the globe. It is reassuring that,
in this study, tolvaptan use did not appear to inﬂuence
our results. Third, we were not able to include early
onset of clinical symptoms in our set of conventional
risk markers, because such data were not routinely
collected. Finally, some of these markers, such as KIM-1
and NGAL, are also found to be associated with acute
kidney injury.40 Because our patients have CKD and
were studied during a routine outpatient clinic, it is
more likely that these markers reﬂect chronic rather
than acute kidney injury in our study.
Strengths of this study are that we have information
on multiple outcome measures, namely, annual change
in eGFR, mGFR, and htTKV. In addition we have
information on type of PKD mutation. This information
has, to our knowledge, not previously been tested in
conjunction with baseline htTKV and eGFR to predict
the rate of disease progression in ADPKD. Importantly,
we showed that urinary biomarkers were associated
with annual change in eGFR even after adjustment for
type of PKD mutation, baseline htTKV, and eGFR.
Finally, all patients performed a 24-hour urineKidney International Reports (2018) 3, 291–301
AL Messchendorp et al.: Urinary biomarkers and ADPKD disease progression CLINICAL RESEARCHcollection for biomarker assessment, which, because of
the circadian rhythm in urinary excretion of these
markers, may be better than the spot urines that are
used in most other studies.
In conclusion, our study showed that urinary b2MG
and MCP-1 excretion is associated with the rate of
kidney function decline in patients with ADPKD
independent of conventional risk markers. We
demonstrated that these urinary biomarkers can be of
value even beyond conventional risk markers in pre-
dicting kidney function decline. Measurement of
urinary tubular damage and inﬂammation markers in
ADPKD patients may therefore become an easy, rapid,
and inexpensive tool to predict the rate of disease
progression. Future studies should, however, corrobo-
rate our ﬁndings before measurement of urinary
biomarkers can be used for this purpose.DISCLOSURE
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SUPPLEMENTARY MATERIAL
Supplementary Methods. Statistical analysis.
Table S1. Correlations among biomarker excretions. b2MG
excretion was correlated with a general marker (albumin),
a distal tubular marker (HFABP) and an inﬂammationKidney International Reports (2018) 3, 291–301marker (NGAL). MCP-1 excretion was correlated with a
general marker (albumin), a glomerular marker (IgG), a
proximal tubular marker (KIM-1) and an inﬂammation
marker (NGAL).
Table S2. AICs and Akaike weights of the various models
for annual change in eGFR. For annual change in eGFR,
model 5 (the resultant of the stepwise backward analysis)
had the lowest AIC. When comparing the w(AIC) of each
model, model 5 had a normalized probability of 1.00 over
model 1, 1.00 over model 2 and 1.00 over model 3, and
0.88 over model 4 indicating that model 5 comes closer
to the truth and is the best model.
Table S3. Associations of the urinary biomarkers with
annual change in eGFR calculated as slope through
multiple ($ 3) eGFR values. b2MG and MCP-1 were both
associated with annual change in eGFR, and remained
signiﬁcant after adjustment for conventional risk markers
(standardized b ¼ 0.32, P ¼ 0.002 and standardized
b ¼ 0.27, P ¼ 0.02 respectively).
Table S4. AICs and Akaike weights for the Mayo htTKV
classiﬁcation and Urinary Biomarker Score. The urinary
biomarker score had the lowest AIC. When comparing
the w(AIC) of each model, the urinary biomarker score
had a normalized probability of 1.00 over the Mayo
htTKV classiﬁcation, indicating that the biomarker score
is preferred over the Mayo htTKV classiﬁcation.
Figure S1. Scatter plot of urinary b2MG and MCP-1 excre-
tion versus annual change in eGFR. This ﬁgure represents
the value distributions of annual change in eGFRwith either
b2MG orMCP-1 excretion. The line represents the results of
the fractional polynomial regression analysis. For b2MG
excretion the association was linear, the association was
non-linear for MCP-1 excretion < 200 ng/24 h.
Figure S2. Differences in annual change in eGFR between
classes of the Mayo htTKV classiﬁcation of ADPKD. This
ﬁgure represents the differences in annual change in
eGFR for the different Mayo htTKV classes. The annual
change in eGFR was 1.2  2.0 ml/min per 1.73 m2 for
class A, 2.5  2.2 ml/min per 1.73 m2 for class B, 2.7
 2.3 ml/min per 1.73 m2 for class C, 3.7  5.5 ml/min
per 1.73 m2 for class D, and 5.7  2.8 ml/min per 1.73
m2 for class E.
Supplementary material is linked to the online version of
the paper at www.kireports.org.REFERENCES
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